Adverse Drug Reaction News Bulletins
ADR News Bulletin 2023 May (Volume 25 Number 1)
16 May 2023
Audiences
Healthcare professional
Industry member
Product-type
Therapeutic Products
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
Bulletin Highlights:
Analysis of adverse event reports with COVID-19 therapeutics for the treatment or prophylaxis of COVID-19
Analysis of adverse event reports for health products for year 2022
Analysis of COVID-19 vaccine adverse event reports for year 2022
High-dose vitamin B6 and risk of peripheral neuropathy
Navigation made easy – explore HSA’s website for adverse event reporting and safety information related to health products
Click on the link below to download the issue in pdf:
ADR_News_May2023_Vol25_No [PDF, 2520 KB] (opens in new tab)
New drugs approved in 2022:
Healthcare professionals are encouraged to report all serious and non-serious
suspected adverse drug reactions (ADRs) with the use of new drugs. Your active
participation in the ADR monitoring programme will provide valuable support to
the post-marketing surveillance on drug safety.
Click on the link below to download the issue in pdf: